375 related articles for article (PubMed ID: 15951264)
21. [The hypereosinophilic syndrome: case report].
Mikołajczyk K; Zaba R; Walkowiak B; Grzybowski G; Samborski W
Ann Acad Med Stetin; 2006; 52 Suppl 2():65-9. PubMed ID: 17471838
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
23. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
Schaller JL; Burkland GA
MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
[TBL] [Abstract][Full Text] [Related]
24. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
25. Eosinophilia: secondary, clonal and idiopathic.
Tefferi A; Patnaik MM; Pardanani A
Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
[TBL] [Abstract][Full Text] [Related]
26. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C
Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038
[No Abstract] [Full Text] [Related]
27. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
[TBL] [Abstract][Full Text] [Related]
28. [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery].
Jönsson S; Lewerin C; Jacobsson S; Wadenvik H
Lakartidningen; 2006 Sep 6-12; 103(36):2556-9. PubMed ID: 17007200
[No Abstract] [Full Text] [Related]
29. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
[No Abstract] [Full Text] [Related]
30. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
31. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533
[TBL] [Abstract][Full Text] [Related]
32. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.
Curtis CE; Grand FH; Musto P; Clark A; Murphy J; Perla G; Minervini MM; Stewart J; Reiter A; Cross NC
Br J Haematol; 2007 Jul; 138(1):77-81. PubMed ID: 17555450
[TBL] [Abstract][Full Text] [Related]
33. Myeloproliferative hypereosinophilic syndrome presenting as cardiac failure and response to imatinib.
Desai N; Morkhandikar S; Sahay R; Jijina F; Patil P
Am J Ther; 2014; 21(2):e35-7. PubMed ID: 24603276
[TBL] [Abstract][Full Text] [Related]
34. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
35. [Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy].
Mauri M; García M; Reynaga E; Ramila E
Med Clin (Barc); 2007 Jun; 129(4):159. PubMed ID: 17663975
[No Abstract] [Full Text] [Related]
36. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
[No Abstract] [Full Text] [Related]
37. The hypereosinophilic syndromes: still more heterogeneity.
Gleich GJ; Leiferman KM
Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
[TBL] [Abstract][Full Text] [Related]
38. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha].
Pottier P; Planchon B; Grossi O
Rev Med Interne; 2003 Aug; 24(8):542-6. PubMed ID: 12888176
[TBL] [Abstract][Full Text] [Related]
39. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor.
Ascione L; De Michele M; Accadia M; Spadaro P; Rumolo S; Tuccillo B
Eur J Echocardiogr; 2004 Oct; 5(5):386-90. PubMed ID: 15341874
[TBL] [Abstract][Full Text] [Related]
40. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
